Research programme: hydroxysteroid dehydrogenase inhibitors - AbbVieAlternative Names: Metabolic syndrome therapy - Abbott
Latest Information Update: 08 Feb 2013
At a glance
- Originator Abbott Laboratories
- Class Amidines
- Mechanism of Action 11-beta hydroxysteroid dehydrogenase type 1 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Research Metabolic syndrome